Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jul 27, 2023
AI Trader's Winning Streak: $ABBV Profits Jump +3.98% in 7 Days

AI Trader's Winning Streak: $ABBV Profits Jump +3.98% in 7 Days

One such innovation is the emergence of AI trading robots that promise to navigate the complexities of the stock market and deliver substantial returns. In this article, we analyze the recent performance of an AI trading robot accessible at "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" and explore how it generated an impressive +3.98% gain while trading ABBV during the previous week. Additionally, we examine the company's momentum indicator and its implications for potential traders.

AI Trading Robot Performance

The "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" AI trading robots have caught the attention of investors with their remarkable performance. During the past week, these bots demonstrated their capabilities by achieving a significant +3.98% gain while trading ABBV, a pharmaceutical company known for its innovative products and steady growth.

Analyzing the Momentum Indicator

One crucial tool employed by traders to gauge a stock's potential momentum is the Momentum Indicator. On July 11, 2023, ABBV's Momentum Indicator surpassed the 0 level, signaling the possibility of a new upward trend for the stock. Traders are likely to interpret this as an opportunity to consider buying the stock or buying call options, expecting a positive price movement.

To gain further insight, Tickeron's A.I.dvisor analyzed 79 similar instances where ABBV's Momentum Indicator turned positive. The findings revealed that in 53 out of the 79 cases, the stock moved higher in the subsequent days. Based on this historical data, the odds of ABBV moving higher after the positive Momentum Indicator reading are calculated to be at an encouraging 67%.

Earnings Results

In addition to the Momentum Indicator, earnings reports play a pivotal role in influencing a company's stock performance. ABBV's last earnings report on April 27 showcased earnings per share (EPS) of $2.46, meeting the estimated value of $2.46. With 1.55 million shares outstanding, this performance led to a current market capitalization of approximately $252.61 billion.

The fact that ABBV met earnings estimates can instill confidence in investors and may support the positive momentum indicated by the AI trading robots. Strong earnings are often perceived as a sign of a company's fundamental strength, attracting more investors and potentially leading to increased demand for the stock.

Summary

AI trading robots have proven their worth in the stock market, and the "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" bots are no exception. Their impressive +3.98% gain while trading ABBV highlights the potential these AI-driven tools hold in generating profits for investors.

Moreover, ABBV's Momentum Indicator moving above the 0 level on July 11, 2023, suggests a potential shift towards an upward trend. Past instances of similar positive Momentum Indicators further reinforce the probability of ABBV experiencing an upward movement, with odds reaching as high as 67%.

Additionally, ABBV's last earnings report meeting the estimated EPS value reflects positively on the company's financial performance, bolstering investor confidence in the stock's future prospects.

Related Ticker: ABBV

Contributor

Dem Sem's AvatarDem Sem|Expert

Momentum Indicator for ABBV turns positive, indicating new upward trend

ABBV saw its Momentum Indicator move above the 0 level on August 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in of 357 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 361 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ABBV moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 70 cases where ABBV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ABBV broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (19.209). ABBV has a moderately high P/E Ratio (73.444) as compared to the industry average of (32.559). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (11.039). Dividend Yield (0.026) settles around the average of (0.028) among similar stocks. P/S Ratio (7.163) is also within normal values, averaging (4.140).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ABBV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 199.61B. The market cap for tickers in the group ranges from 72.83K to 1.03T. LLY holds the highest valuation in this group at 1.03T. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 9%. PFE experienced the highest price growth at 2%, while LLY experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 26%. For the same stocks of the Industry, the average monthly volume growth was -18% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 24
P/E Growth Rating: 56
Price Growth Rating: 45
SMR Rating: 55
Profit Risk Rating: 62
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
ABBV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Profile
Details
Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
50000
Web
http://www.abbvieinvestor.com
Interact to see
Advertisement
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.
AXON surged approximately +17.56% on February 25, 2026, closing at $520.18 versus the prior session's close of $442.51. The primary catalyst was a blowout Q4 2025 earnings report, with adjusted EPS of $2.15 crushing the consensus estimate of approximately $1.67.
CAVA shares surged approximately +25.01% on February 25, 2026, closing near $84.76, up from the prior session's close of $67.80. The primary catalyst was a better-than-expected Q4 fiscal 2025 earnings report, with EPS of $0.04 beating the $0.03 consensus estimate and revenue of ~$274.99M exceeding the $268.04M estimate.
ODD shares plunged approximately 49.21% on February 25, 2026, closing near $14.74, compared to the prior close of approximately $29.02. The primary catalyst was a shock Q1 2026 revenue warning: management guided for a roughly 30% year-over-year revenue decline due to a severe spike in customer acquisition costs (CAC).
MNKD shares collapsed 36.82% on February 25, 2026, closing at $3.50 versus the prior session's close of $5.54 — one of the largest single-day declines in the stock's recent history. The primary catalyst was United Therapeutics' surprise unveiling of Tresmi, a proprietary soft mist inhaler delivering treprostinil, announced during the company's Q4 2025 earnings call.
EOSE shares fell sharply on February 26, 2026, dropping approximately 31% from the prior session's close of $11.13 to around $7.64 in early trading, following a pre-market earnings release. Primary catalyst: Eos Energy reported Q4 2025 non-GAAP EPS of -$0.72, missing analyst consensus estimates by $0.48, a 200%+ negative surprise.
ARRY beat Q4 revenue expectations but showed a sharp year‑over‑year sales decline and a sizeable net loss. Adjusted EBITDA for Q4 badly missed Wall Street estimates, highlighting ongoing margin and cost pressures. 2026 guidance for EPS and EBITDA came in well below analyst forecasts, signaling weaker‑than‑hoped earnings power over the next year.
C3.ai (AI) dropped more than 18% today after delivering a deeply disappointing quarterly report, slashing its revenue outlook, and announcing mass layoffs, which together reinforced doubts about its growth story in an increasingly competitive AI software market.
On the surface, PRCT’s top line still grew: Q4 2025 revenue reached about 76.4 million dollars, up roughly 11.9–12% from the prior year. However, analysts had expected something closer to 94–96 million dollars, so the shortfall of nearly 20% was significant for a high‑growth med‑tech name.
Payoneer Global (PAYO) fell more than 18% today after it missed Wall Street expectations on both Q4 2025 revenue and earnings, and issued softer‑than‑hoped guidance that reinforced concerns about slowing growth and competitive pressure in cross‑border fintech.
Gold, uranium, and rare earth stocks are moving fast in 2026 — and this 15-minute AI Trading Agent is built to move faster. Designed for high-beta Mining & Metals leaders like NEM, LEU, MP, and KGC, it transforms commodity volatility into structured, data-driven opportunity with institutional-grade risk control.
In a market where milliseconds matter and emotional decisions cost fortunes, a new class of AI-driven trading tools is rewriting the rulebook. Meet the HUBB, AVGO, ITA, QQQ – Trading Results AI Trading Agent (4 Tickers, 5min) — a precision-engineered robot that monitors four strategically selected tickers across semiconductors, industrial power infrastructure, aerospace & defense, and broad tech growth.
Q4 2025 gross profit grew about 24% year over year to roughly 2.87 billion dollars, with Cash App gross profit up about 33% and Square gross profit up around 7%. Adjusted operating income jumped to about 588 million dollars in Q4 (around a 20% margin), up strongly from the prior year. For the full year, gross profit was roughly 10.36 billion dollars, up about 17% year over year, showing broad‑based growth across the business.
NVDA shares declined 5.47% on Thursday, February 26, 2026, closing at $184.87, down from the prior session close of approximately $195.56. The primary catalyst was a "sell the news" reaction to Q4 fiscal 2026 earnings that beat estimates on every headline metric but failed to ignite meaningful buying interest.
Shares of UHS fell approximately 9.15% on February 26, 2026, closing near $209.62, down from a prior close of $230.73. The primary catalyst was a mixed Q4 2025 earnings report: adjusted EPS of $5.88 missed the consensus estimate of $5.92, and revenue of $4.49 billion fell short of the $4.50–$4.51 billion analyst forecast.
HEI shares fell approximately 9.21% on February 26, 2026, closing at $312.98 versus a prior close near $344.72. The primary catalyst was HEICO's Q1 fiscal 2026 earnings report, which delivered headline beats on EPS and revenue but disappointed investors on margin quality, Adjusted EBITDA, and cash flow generation.